[go: up one dir, main page]

SI1814595T1 - Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina - Google Patents

Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Info

Publication number
SI1814595T1
SI1814595T1 SI200531838T SI200531838T SI1814595T1 SI 1814595 T1 SI1814595 T1 SI 1814595T1 SI 200531838 T SI200531838 T SI 200531838T SI 200531838 T SI200531838 T SI 200531838T SI 1814595 T1 SI1814595 T1 SI 1814595T1
Authority
SI
Slovenia
Prior art keywords
perturbs
oligonucleotide
cancer
agent
treatment
Prior art date
Application number
SI200531838T
Other languages
English (en)
Inventor
Martin Gleave
Gabriella Zupi
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of SI1814595T1 publication Critical patent/SI1814595T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200531838T 2004-11-23 2005-11-22 Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina SI1814595T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US52296004P 2004-11-24 2004-11-24
EP05810600.6A EP1814595B1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (1)

Publication Number Publication Date
SI1814595T1 true SI1814595T1 (sl) 2014-06-30

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531838T SI1814595T1 (sl) 2004-11-23 2005-11-22 Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Country Status (11)

Country Link
US (2) US20080014198A1 (sl)
EP (1) EP1814595B1 (sl)
JP (1) JP4980919B2 (sl)
AU (1) AU2005309274B2 (sl)
CA (1) CA2584646C (sl)
DK (1) DK1814595T3 (sl)
ES (1) ES2456017T3 (sl)
PL (1) PL1814595T3 (sl)
PT (1) PT1814595E (sl)
SI (1) SI1814595T1 (sl)
WO (1) WO2006056054A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US20080014198A1 (en) * 2004-11-23 2008-01-17 The University Of British Columbia Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
MX2013010524A (es) 2011-03-15 2013-12-06 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
EA201491568A1 (ru) * 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
JPH09506770A (ja) * 1993-12-23 1997-07-08 バイオグノステック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング ｃ−ｅｒｂＢの発現が関与する疾患を予防及び治療するためのアンチセンス核酸
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JP4293636B2 (ja) * 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100820266B1 (ko) * 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
KR101166214B1 (ko) * 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
US7019017B2 (en) * 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
DE60333839D1 (de) * 2002-08-21 2010-09-30 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
CA2882443C (en) * 2002-08-21 2016-12-13 The University Of British Columbia Rnai probes targeting cancer-related proteins
JP2007523839A (ja) * 2003-04-18 2007-08-23 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 血管新生性障害の治療法
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US20080014198A1 (en) * 2004-11-23 2008-01-17 The University Of British Columbia Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels

Also Published As

Publication number Publication date
EP1814595A4 (en) 2009-04-15
AU2005309274B2 (en) 2011-07-21
WO2006056054A1 (en) 2006-06-01
EP1814595A1 (en) 2007-08-08
EP1814595B1 (en) 2014-01-08
JP2008520591A (ja) 2008-06-19
PL1814595T3 (pl) 2014-08-29
CA2584646C (en) 2015-11-03
AU2005309274A1 (en) 2006-06-01
CA2584646A1 (en) 2006-06-01
US20080014198A1 (en) 2008-01-17
PT1814595E (pt) 2014-04-02
US20110142827A1 (en) 2011-06-16
JP4980919B2 (ja) 2012-07-18
DK1814595T3 (da) 2014-03-31
ES2456017T3 (es) 2014-04-21

Similar Documents

Publication Publication Date Title
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
IL187898A0 (en) Parp modulators and treatment of cancer
IL186662A0 (en) Combination cancer therapy with
EP1727498A4 (en) DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
PT2365723T (pt) Transmissão localizada e distribuída
IL198305A0 (en) Cancer susceptibility variants on chr8q24.21
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
IL164563A0 (en) Prostate treatment stent
EP2022512A4 (en) CATHETER HOSE AND CATHETER WITH HOSE
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
EP1804891A4 (en) CAVITATION-IMPROVED TREATMENT THROUGH LOCAL LEVY
IL192144A0 (en) Combination comprising combretastatin and anticancer agents
GB0428180D0 (en) Combination therapy
PT1814595E (pt) Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
GB0417481D0 (en) Combination therapy
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
PL1806134T3 (pl) Środek i produkt żywnościowy do zapobiegania/leczenia czynnościowych zaburzeń trawiennych
GB0424339D0 (en) Combination therapy
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428187D0 (en) Cancer treatment
ZA200610032B (en) Oculoselective drugs and prodrugs
GB0428170D0 (en) Mono and Combination Therapy
GB0413346D0 (en) Treating cancer